Wemos in EenVandaag: patent protection Covid-19 vaccine affects low- & middle-income countries

It was a much-needed optimistic headline in recent days: the developments around the pharmaceutical company Pfizer’s new COVID-19 vaccine are in the final stages. However, Pfizer has so far refused to give up the vaccine’s patent protection. This limits production and increases the price per vaccine – threatening access and distribution in low- and middle-income countries in particular. On November 20, Wemos’ global health advocate Tom Buis held an interview about this news in the Dutch programme EenVandaag.

Read more here (Dutch).

Photo: EenVandaag